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Objectives. The Veterans Affairs Non-Q-Wave Infarction Strat-
egies In-Hospital (VANQWISH) trial was designed to compare
outcomes of patients with a non–Q wave myocardial infarction
(NQMI) who were randomized prospectively to an early “inva-
sive” strategy versus an early “conservative” strategy. The pri-
mary objective was to compare early and late outcomes between the
two strategies using a combined trial end point (all-cause mortality
or nonfatal infarction) during at least 1 year of follow-up.
Background. Because of the widely held view that survivors of
NQMI are at high risk for subsequent cardiac events, manage-
ment of these patients has become more aggressive during the last
decade. There is a paucity of data from controlled trials to support
such an approach, however.
Methods. Appropriate patients with a new NQMI were random-
ized to an early “invasive” strategy (routine coronary angiography
followed by myocardial revascularization, if feasible) versus an
early “conservative” strategy (noninvasive, predischarge stress
testing with planar thallium scintigraphy and radionuclide ven-
triculography), where the use of coronary angiography and myo-
cardial revascularization was guided by the development of isch-
emia (clinical course or results of noninvasive tests, or both).
Results. A total of 920 patients were randomized (mean
follow-up 23 months, range 12 to 44). The mean patient age was
61 6 10 years; 97% were male; 38% had ST segment depression at
study entry; 30% had an anterior NQMI; 54% were hypertensive;
26% had diabetes requiring insulin; 43% were current smokers;
43% had a previous acute myocardial infarction; and 45% had
antecedent angina within 3 weeks of the index NQMI.
Conclusions. Baseline characteristics were compatible with a
moderate to high risk group of patients with an NQMI.
(J Am Coll Cardiol 1998;31:312–20)
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Approximately 50% of the 1.5 million patients in the United
States who sustain an acute myocardial infarction (AMI) each
year have non–Q wave myocardial infarction (NQMI) (1–3).
The percentage of NQMIs has increased over the past two
decades, probably due to a variety of factors (4,5). Because of
the widespread use of both aspirin and thrombolytic agents in
AMI, 40% to 45% of patients who present with acute ST
segment elevation do not have electrocardiographic (ECG) Q
waves after thrombolysis (6–9), thus contributing to the ex-
panding pool of patients with NQMI.
Despite a more favorable early prognosis, long-term sur-
vival of patients with NQMI is similar to that of patients who
have had a Q wave AMI (10,11). The higher rate of infarct
extension and postinfarction ischemia after NQMI (10–14)
resulted in a more aggressive approach to diagnosis and
treatment. The 1987 American College of Cardiology/
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American Heart Association (ACC/AHA) Joint Task Force
Report on Guidelines for Coronary Arteriography recom-
mended that NQMI (even in asymptomatic patients) consti-
tuted a class I (“definite”) indication for diagnostic coronary
angiography (15). This 10-year old recommendation, not de-
rived from prospective, randomized trials, contrasted with the
approach often applied after Q wave AMI, where only higher
risk patients were recommended to undergo coronary angiog-
raphy. Even though the recently published ACC/AHA Guide-
lines for the Management of Patients With Acute Myocardial
Infarction (16) reclassified coronary angiography after NQMI
as a class IIb indication (usefulness/efficacy is not established
by evidence/opinion), an aggressive approach to early invasive
management of NQMI has become firmly entrenched in
clinical practice.
The utility of routine invasive testing in the management of
survivors of AMI remains uncertain. Published findings in
post-AMI patients with ST segment elevation (Thrombolysis in
Myocardial Infarction-IIB trial [TIMI-IIB]) (17) or ST seg-
ment depression (TIMI-IIIB trial) (18) have suggested that the
routine use of invasive testing followed by myocardial revas-
cularization may result in unnecessary diagnostic and interven-
tional procedures. Recently published data from Global Use of
Strategies to Open Occluded Arteries (GUSTO) demon-
strated no improvement in clinical outcomes in regions of the
United States where angiography and angioplasty were per-
formed more frequently (19). Moreover, it remains unproven
whether these procedures improve quality of life (20).
We initiated a prospective, randomized trial at 15 Depart-
ment of Veterans Affairs medical centers, from which 920
patients with NQMI were randomized to an early “invasive”
versus an early “conservative” strategy. The primary objective
was to compare early and late outcomes between the two
randomized management strategies using a combined trial end
point (all-cause mortality or nonfatal infarction) during 12 to
44 months of follow-up. Secondary objectives included analysis
of risk stratification covariates and detailed cost-effectiveness
comparisons, including functional status and quality of life
assessments.
Methods
Ethics, approval process and written informed consent.
This Department of Veterans Affairs Cooperative Study (CS
no. 368), known as the Veterans Affairs Non-Q-Wave Infarc-
tion Strategies In-Hospital (VANQWISH) trial, was approved
by the Palo Alto Cooperative Studies Program Human Rights
Committee and by the Cooperative Studies Evaluation Com-
mittee in 1991. Patient recruitment began on April 14, 1993.
The protocol and consent form were approved by the Institu-
tional Review Boards at each of the 15 Department of
Veterans Affairs medical centers.
Objectives. The primary objective was to test the hypoth-
esis that patients recovering from NQMI would have equiva-
lent long-term clinical outcomes (all-cause mortality or recur-
rent nonfatal infarction), using either an early conservative or
invasive diagnostic strategy. The invasive strategy consisted of
routine diagnostic coronary angiography (“anatomic” risk as-
sessment). The conservative strategy consisted of selective,
specialized, noninvasive testing (“functional” risk assessment).
An important secondary objective was to establish clinical,
demographic, ECG, laboratory and diagnostic risk factors for
patients with NQMI at hospital discharge and during long-
term follow-up. Other secondary objectives were to assess
direct and indirect costs and other health care outcomes
(functional status and quality of life).
Patient selection. Patients with suspected NQMI were
screened for trial eligibility by study coordinators during
hospital admission. Serial 12-lead ECGs and cardiac enzymes
(creatine kinase [CK], lactic dehydrogenase [LDH] and serum
glutamic oxaloacetic transaminase [SGOT]) and isoenzymes
(CK-MB) were obtained on hospital entry and at regular
intervals for 24 to 72 h. Patients were eligible to receive any
therapy considered to be standard care during the early course
of the hospital period. Inclusion and exclusion criteria are
summarized in Table 1.
Electrocardiographic and enzymatic diagnosis. The ECG
analysis was modeled after the Atlanta code in which serial
tracings were obtained at multiple time points after NQMI
symptom onset during the initial 24 to 72 h in the coronary care
unit (4). At least one ECG was obtained 48 h after hospital
admission to exclude the late development of Q waves, the vast
majority of which (80%) occur within that period (21). Patients
were excluded from the study if they had abnormal Q waves
(i.e., 30 ms in duration in two leads within a given lead group)
or R waves (i.e., 40 ms in lead V1 and an R/S ratio of 1 in lead
V2) (22).
Acute ST segment displacement or T wave inversions were
not prerequisites. Significant ST segment shifts were defined as
the presence of 1 mm of ST segment elevation, depression or
T wave inversion (or, in the presence of left ventricular
hypertrophy, 2 mm of ST segment depression) in two leads
within a given NQMI location.
Serial ECGs were interpreted by site investigators and
forwarded to a core laboratory for subsequent analysis. For the
purpose of stratifying patients between randomized strategy
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American Heart
Association
AMI 5 acute myocardial infarction
CK 5 creatine kinase
ECG 5 electrocardiogram, electrocardiographic
GUSTO IIa 5 Global Use of Strategies to Open Occluded
Arteries
LDH 5 lactic dehydrogenase
NQMI 5 non–Q wave myocardial infarction
SGOT 5 serum glutamic oxaloacetic transaminase
TIMI 5 Thrombolysis in Myocardial Infarction
VANQWISH 5 Veterans Affairs Non-Q-Wave Infarction
Strategies In-Hospital
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assignments, the designations of “anterior versus nonanterior”
location and “ST segment depression versus no ST segment
depression” were derived from the entry ECG, whereas data
for coding baseline ECGs were derived from the tracing judged
by the site investigator to be most representative of all serial
tracings obtained within the initial 24 to 72 h of NQMI onset.
Thus, certain discrepancies may be apparent between various
ECG categories derived at the time of randomization (block-
ing variables) and at “study baseline” (24 to 72 h after index
NQMI).
For patient qualification, one or more cardiac enzymes
(total CK, LDH, SGOT) had to be 1.5 times the hospital’s
upper normal laboratory limit and/or two consecutive total CK
and CK-MB determinations separated by 4 h had to exceed the
upper normal limit.
Randomization procedure. Patients who met study entry
criteria and gave written, informed consent were randomized,
using the adaptive allocation (biased coin) procedure (23).
This procedure maximized the probability that the number of
patients allocated to each strategy was balanced within center
and for each of the following five prognostic (stratifying)
variables: age (,60 or $60 years), previous AMI (yes/no), use
of thrombolytic agents (yes/no), AMI location by ECG (anterior/
nonanterior) and entry ST segment depression (yes/no).
Experimental protocol. Randomization occurred typically
within 1 to 3 days of NQMI onset, generally on transfer from
the coronary care unit. Patients transferred from an outlying
hospital center were randomized within 7 days of clinical and
enzymatic NQMI onset. The protocol summarizing patient
management is depicted in Figure 1. For patients assigned to
the invasive strategy, early diagnostic coronary angiography
was performed as the initial post-NQMI test, generally within
3 to 7 days after NQMI onset. Decisions to proceed with
additional noninvasive testing or myocardial revascularization
were left to the discretion of the investigators. TIMI-IIIB
management guidelines for revascularization were followed
(18): patients with significant single-vessel coronary artery
disease were considered candidates for percutaneous translu-
minal coronary angioplasty or atherectomy, whereas coronary
artery bypass graft surgery was recommended for multivessel
disease. The decision to revascularize a “culprit” stenosis only,
to perform a “complete” revascularization procedure or to
continue medical therapy was left to the individual investiga-
tor’s discretion. Whenever appropriate, all study patients re-
ceived enteric-coated aspirin, 325 mg/day, and diltiazem
(Cardizem CD), 180 to 300 mg/day, based on previously
published data supporting this therapy as a secondary preven-
tion in NQMI (24–26).
For patients randomized to the conservative strategy, a
radionuclide ventriculogram to assess left ventricular function
was performed as the first noninvasive test, generally 3 to 7
days after NQMI. Coronary angiography was not required if
the ejection fraction was reduced. Before hospital discharge (6
to 9 days after NQMI), a symptom-limited (standard Bruce)
treadmill exercise test was performed with planar or single-
photon emission computed tomographic thallium scintigraphy.
In patients who could not achieve 5 metabolic equivalents of
exercise, an intravenous infusion of dipyridamole, 0.56 mg/kg,
was administered, after which thallium scintigraphy was per-
formed. To ensure quality and accuracy, each participating site
was required to submit examples of thallium studies and to
correctly interpret “unknowns” provided by the Nuclear Car-
diology Laboratory (see Appendix) before initiation of the
trial.
Coronary angiography with or without myocardial revascu-
larization was performed in patients randomized to the con-
servative strategy only if one or more of the following criteria
were satisfied: 1) clinical criterion—the patient developed
recurrent post-NQMI angina associated with ischemic ECG
changes; 2) exercise ECG criterion—the patient exhibited
$2 mm of ST segment deviation during peak exercise; 3)
thallium scintigraphic criterion—the patient displayed two or
more redistribution defects or one redistribution defect plus
increased lung uptake of thallium.
Decisions to perform myocardial revascularization in pa-
tients assigned to either strategy were made by the local site
investigator, using the results of invasive or noninvasive tests,
or both, performed at his or her institution. For patients
Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria
1. Age 18 years (no upper age limit for trial enrollment)
2. Clinical history compatible with AMI
3. Biochemical confirmation of myocardial necrosis, based on an abnormal
rise of cardiac enzymes (CK, LDH, SGOT) or CK-MB activity above
upper normal limit for the individual hospital laboratory
4. Absence of new ECG Q waves (0.04 s in duration; 0.1 mV in amplitude)
or R waves (0.04 s in lead V1; R/S ratio 5 1 in lead V2) in two or more
leads within one of three lead groups (anterior 5 leads V1 to V4; inferior
5 leads II, III and aVF; lateral 5 leads I, aVL, V5 and V6)
5. Patient physically able to undergo invasive or noninvasive diagnostic
testing
Exclusion Criteria
1. Unstable angina or angina refractory to intensive medical therapy during
hospital period after NQMI
2. Persistent left bundle branch block
3. Congestive heart failure that does not clear with medical therapy
4. Cardiogenic shock
5. Ventricular fibrillation or symptomatic ventricular tachycardia . 48 h
after index NQMI
6. Pericarditis
7. CABG or PTCA within 3 mo preceding randomization
8. Participation in another clinical research trial or use of an investigational
drug within previous 30 days
9. Inability to undergo testing or to cooperate with protocol
10. Family/home circumstances that would preclude follow-up
11. Concomitant severe illness or comorbidity that might adversely affect
follow-up during trial
12. Inability/unwillingness to provide informed, written consent
AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass graft
surgery; CK 5 creatine kinase; CK-MB 5 creatine kinase, MB isoenzyme;
ECG 5 electrocardiographic; LDH 5 lactic dehydrogenase; NQMI 5 non–Q
wave myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; SGOT 5 serum glutamic oxaloacetic transaminase.
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assigned to the invasive arm in whom coronary angiographic
findings were “equivocal” for significant stenosis, optional
noninvasive testing could be obtained as needed. All coronary
angiograms were forwarded subsequently to a core laboratory
for subsequent blinded review and coding (see Appendix), but
these centrally obtained interpretations were not used for local
decision-making.
Patient intake and follow-up. Patient intake ended on
December 31, 1995, after the enrollment of 920 patients, and
the trial concluded on December 31, 1996. Study patients were
seen at 1 month after hospital discharge and at 3-month
intervals until trial termination. Patient follow-up ranged from
12 to 44 months (average 23). Electrocardiograms were ob-
tained at 1, 3 and 12 months and annually until trial termina-
tion. Quality of life assessments and questionnaires were
obtained at 1 and 12 months of follow-up and at the final visit.
End points. The primary end point of the trial was all-
cause mortality or recurrent nonfatal AMI, whichever oc-
curred first during a minimal 12-month follow-up period.
Secondary end points included Kaplan-Meier estimates of
cumulative event-free survival, hospital readmissions for un-
stable angina, need for myocardial revascularization, major
procedural complications after coronary angiography or myo-
cardial revascularization, quality of life assessments and re-
source utilization between the two strategies.
Statistical methodology. The trial was designed to evaluate
whether the primary end point rates for the two strategy
groups were equivalent during cumulative follow-up (12 to 44
months; mean 2.5 years). Sample size was calculated using the
formula of Makuch and Simon (27) for an equivalence study
design based on binomial proportions. The assumptions in-
cluded an end point rate of 20% in each group during
12-month follow-up (28,29); a intergroup difference of 7.5%
(the minimal group difference judged to be of clinical signifi-
cance); a 5% two-sided significance level; and 80% power. The
calculated sample size of 894 patients was inflated to the target
of 922 patients (461 per group) to adjust for a projected 3%
lost to follow-up rate during the first 12 months of follow-up.
Formal interim analyses for efficacy were conducted as
requested by the Data Monitoring Board, using the method of
Figure 1. Trial design of VANQWISH. ASA 5
acetylsalicyclic acid (aspirin); CABG 5 coronary
artery bypass graft surgery; CATH 5 catheteriza-
tion; CCU 5 coronary care unit; MED Rx 5
medical drugs; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary an-
gioplasty; REVASC 5 revascularization; RVG 5
radionuclide ventriculography; D’s 5 changes.
315JACC Vol. 31, No. 2 FERRY ET AL.
February 1998:312–20 DESIGN AND CHARACTERISTICS OF VANQWISH
Lan and DeMets (30) with an O’Brien-Fleming type spending
function (31), which adjusted for multiple looks at the data
while preserving a near nominal overall significance level.
Patients who did not adhere to the assigned strategy were
included as randomized in analyses (i.e., by intention-to-treat).
Results
Figure 2 presents a summary of patient selection and
randomization. A total of 21,449 patients with a suspected
acute coronary syndrome was screened during 32.5 months of
recruitment. Of these patients, 2,738 patients had evidence of
evolving NQMI, 920 of whom (34%) were randomized. This
high proportion of patients with NQMI who were randomized
to the VANQWISH trial supports external generalizability of
subsequent trial results.
The adaptive allocation randomization procedure resulted
in balanced distribution of patients at each site according to
the stratifying variables and protocol strategy. Baseline char-
acteristics by stratifying variables are presented in Table 2.
Table 3 summarizes the baseline clinical characteristics for
the entire study group. A high percentage of patients had
smoked previously (86%), about half of whom (43%) were
current smokers. Fifty-four percent were hypertensive, 26%
had diabetes requiring insulin and 18% had peripheral vascu-
lar disease, but only 17% reported a history of hypercholester-
olemia under treatment.
Of note, 43% of patients had a history of angina and 45%
had antecedent angina within 3 weeks of NQMI. Of this group,
63% had at least Canadian Cardiovascular Society class II
angina. These clinical characteristics are compatible with a
moderate to high risk group of patients with NQMI.
Cardiac medications at hospital admission included aspirin
(46%), calcium channel blockers (36%), nitrates (31%), beta-
blockers (22%), diuretics (22%), angiotensin-converting en-
zyme inhibitors (22%), a lipid-lowering agent (13%), digitalis
(9%) and warfarin (5%).
The randomization ECG demonstrated a spectrum of find-
ings, as illustrated in Table 4. More than half of the patients
(57%) did not have ST segment shifts (ST segment elevation or
depression) on the qualifying tracing, and 21% had no ECG
changes at all. Approximately 30% presented with ST segment
elevation. T wave inversion was common (49%); left ventric-
ular hypertrophy was uncommon (11%); and one-quarter of
the patients had previous Q waves. The slight discrepancy in
the reported rate of anterior AMI location between Tables 2
Figure 2. Randomization of pa-
tients to the VANQWISH trial.
There were 1,561 protocol-eligible
NQMI patients, 920 of whom were
subsequently randomized (59%);
among all eligible NQMI patients
(n 5 2,247), 41% were randomized,
and among all (eligible plus ineligi-
ble) NQMI patients (n 5 2,738),
34% were randomized. A total of
247 (9%) of all eligible NQMI pa-
tients were excluded for “very high
risk” attributes (unstable angina af-
ter infarction, congestive heart fail-
ure that did not respond to medical
therapy, cardiogenic shock or
symptomatic ventricular arrhyth-
mia). ICU 5 intensive care unit;
LBBB 5 left bundle branch block;
other abbreviations as in Fig. 1.
Table 2. Distribution by Randomization Variables*
Invasive Strategy
[no. (%) of pts]
Conservative Strategy
[no. (%) of pts]
Age , 60 yr (n 5 363) 180 (39.0%) 183 (40.0%)
ST seg depression on
admitting ECG (n 5 355)
182 (39.4%) 173 (37.8%)
Ant infarct location (n 5 277) 136 (29.4%) 141 (30.8%)
Previous AMI (n 5 396) 199 (43.1%) 197 (43.0%)
Received thrombolytic therapy
(n 5 115)
58 (12.6%) 57 (12.5%)
*p 5 NS for all comparisons. Ant 5 anterior; Pts 5 patients; seg 5 segment;
other abbreviations as in Table 1.
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and 5 was due to the occasional use of different ECGs for the
randomization procedure (“entry” tracing) and the baseline
tracing (most representative ECG for evolving NQMI).
Of the 272 (30%) of 920 patients who presented with ST
segment elevation, 97 (36%) received thrombolytic therapy. A
total of 115 patients (13%) received thrombolytic therapy.
Some patients who had ST segment elevation did not meet
accepted ECG criteria or had contraindications to thrombo-
lytic therapy; 18 patients without ST segment elevation also
received thrombolytic therapy.
Table 5 presents the characteristics of the patients accord-
ing to their treatment with thrombolytic therapy. Patients who
received thrombolytic therapy were slightly younger (58.6 vs.
61.8 years), were much more likely to be current smokers (62%
vs. 41%) and were much less likely to have hypertension (36%
vs. 57%) or diabetes (13% vs. 28%).
Discussion
Aggressive approach to post-NQMI evaluation. Postinfarc-
tion angina, reinfarction and increased late mortality are
important ischemia-related complications of patients recover-
ing from NQMI (10–14,20,29). Although both observational
(32–38) and retrospective analyses (39–43) suggest that high
and low risk subsets can be identified, that ischemia-related
complications occur in 40% of survivors and that conservative
management may be appropriate for most patients with
NQMI, the overall diagnostic and therapeutic approach to
these patients has become more aggressive during the last
decade. This practice is based on the presumption that an
Table 4. Characteristics of Randomization Electrocardiogram*
Invasive Strategy
[no. (%) of pts]
Conservative Strategy
[no. (%) of pts]
Any ST seg changes (n 5 397) 199 (43.3%) 198 (43.2%)
ST seg elevation (n 5 272) 137 (29.8%) 135 (29.5%)
ST seg depression (n 5 356) 177 (38.5%) 179 (39.1%)
T wave inversion (n 5 448) 224 (48.7%) 224 (48.9%)
Preexisting Q waves (n 5 225) 107 (23.3%) 118 (25.8%)
LVH (n 5 104) 58 (12.6%) 46 (10.0%)
Infarct location†
Anterior (n 5 392) 204 (44.4%) 188 (41.1%)
Inferior (n 5 504) 250 (54.4%) 254 (55.5%)
Lateral (n 5 338) 166 (36.1%) 172 (37.6%)
Posterior (n 5 119) 55 (12.0%) 64 (14.0%)
Any localized infarct (n 5 728) 369 (80.2%) 359 (78.4%)
*p 5 NS for all comparisons. †Patients may have more than one infarct
location. LVH 5 left ventricular hypertrophy; other abbreviations as in Tables 1
and 2.




(Tx vs. no Tx)
Age (yr) (mean 6 SD) 0.0019
58.6 6 9.6 115 (12.4%)
61.8 6 10.3 805 (87.6%)
Risk factors for CAD
Ever-smoked (n 5 787) 100 (87.7%) 687 (85.4%) NS
Current smoker (n 5 399) 71 (62.3%) 328 (40.8%) , 0.0001
Family history of CAD
(n 5 343)
46 (40.1%) 297 (36.9%) NS
Hypertension (n 5 498) 41 (38.0%) 457 (56.8%) , 0.0001
Hypercholesterolemia
(n 5 157)
10 (8.8%) 147 (18.3%) 0.017
Diabetes (n 5 240) 15 (13.2%) 225 (28.0%) 0.001
Procedures . 3 mo before
admission
PTCA (n 5 84) 8 (7.0%) 76 (9.4%) NS
CABG (n 5 156) 15 (13.2%) 141 (17.5%) NS
Angina in 3 wk before admission
(n 5 409)




11 (9.7%) 87 (10.8%) NS
Peripheral vascular disease
(n 5 166)
12 (10.5%) 154 (19.1%) 0.035
*One patient who received thrombolytic therapy died before baseline
information could be obtained. †Treatment versus no treatment. Data are
presented as number (%) of patients. Tx 5 treatment; other abbreviations as in
Table 3.
Table 3. Baseline Characteristics of 919 Patients*†
Invasive Strategy
[no. (%) of pts]
Conservative Strategy
[no. (%) of pts]
Gender
Male (n 5 895) 447 (97.0%) 448 (97.8%)
Female (n 5 895) 14 (3.0%) 10 (2.2%)
Age (yr) (mean 6 SD)
61.8 6 10.0 461 (50.2%)
61.0 6 10.5 458 (49.8%)
Race
White (n 5 683) 344 (74.6%) 339 (74.0%)
Black (n 5 107) 57 (12.4%) 50 (10.9%)
Hispanic (n 5 100) 45 (9.8%) 55 (12.0%)
Other (n 5 29) 15 (3.3%) 14 (3.1%)
Risk factors for CAD
Ever-smoked (n 5 787) 391 (84.8%) 396 (86.5%)
Current smoker (n 5 399) 189 (41.0%) 210 (45.9%)
Family history of CAD (n 5 343) 175 (38.0%) 168 (36.7%)
Hypertension (n 5 498) 262 (56.8%) 236 (51.5%)
Hypercholesterolemia (n 5 157) 80 (17.4%) 77 (16.8%)
Diabetes (n 5 240) 115 (25.0%) 125 (27.3%)
Procedures . 3 mo before admission
PTCA (n 5 84) 40 (8.7%) 44 (9.6%)
CABG (n 5 156) 88 (19.1%) 68 (14.9%)
Angina in 3 wk before admission
(n 5 409)




54 (11.7%) 44 (9.6%)
Peripheral vascular disease
(n 5 166)
84 (18.2%) 82 (17.9%)
*One patient died before baseline information could be obtained. †p 5 NS
for all comparisons. CAD 5 coronary artery disease; other abbreviations as in
Tables 1 and 2.
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invasive strategy of routine coronary angiography is superior to
a conservative strategy of noninvasive stress testing with selec-
tive revascularization in patients who are at risk for developing
adverse ischemic outcomes.
Previous NQMI trials. There are few prospective trials to
guide clinical decision-making in the management of NQMI.
The TIMI-IIIB trial (18) was the only published multicenter
clinical trial to prospectively examine the impact of randomly
assigned diagnostic and therapeutic strategies on short-term
outcome in patients recovering from NQMI. The primary
objective of the TIMI-IIIB trial was to assess 6-week outcomes
in a large group of patients with unstable angina or NQMI,
randomized to either an early invasive or early conservative
strategy. Only 476 (32%) 1,473 patients had NQMI, 252 of
whom were randomized to the early invasive strategy and 224
to the early conservative strategy. There were 18 deaths or
recurrent nonfatal AMIs in the invasive strategy group and 22
in the conservative strategy groups at 6 weeks (p 5 0.30) (18).
TIMI-IIIB was not powered to detect differences in man-
agement strategies in the subset of patients with NQMI.
Moreover, among the 733 patients randomized to the early
conservative strategy in TIMI-IIIB, 64% underwent diagnostic
coronary angiography before day 42, and 90% underwent
coronary angiography before hospital discharge (18). This high
“crossover” rate and the short period of follow-up limit
TIMI-IIIB’s usefulness to provide clinically meaningful com-
parisons between the two strategies.
ST segment elevation versus ST segment depression and
thrombolytic therapy. When our study was designed in 1992, it
was not clear that the direction of ST segment deviation was
associated with a different response to thrombolytic therapy.
Not until the TIMI-IIIB trial was published in 1994 (18) did it
become apparent that only patients presenting with ST seg-
ment elevation were benefited by thrombolytic therapy.
Furthermore, patients who received thrombolytic therapy
in this study had different baseline cardiovascular risks. They
were strikingly more likely to be current smokers and much
less likely to have hypertension or diabetes. They also had a
lower prevalence of peripheral vascular disease and known
hypercholesterolemia and were slightly younger.
Patients may be more likely to present with ST segment
elevation if they have plaque rupture without previous suffi-
cient flow-limiting disease to stimulate the development of
collateral channels. Multiple moderate lesions in major coro-
nary arteries or branch vessels (“diffuse disease”) are more
likely to be present in patients who have multiple cardiac risk
factors. Plaque rupture in these patients may jeopardize less
myocardium, and thus patients may present with ST segment
depression, T wave inversion or no ECG changes (i.e., with
NQMI). Also, cigarette smoking decreases high density li-
poprotein cholesterol, stimulates platelet aggregation, pro-
motes vasoconstriction, increases myocardial oxygen demand,
reduces oxygen supply by the presence of carboxyhemoglobin
and increases fibrinogen levels (44–47). These factors are
more likely to result in a “catastrophic event” in the case of
plaque rupture among patients who present with ST segment
elevation.
Finally, because we had no way of anticipating the nonho-
mogeneity of the thrombolytic and nonthrombolytic NQMI
populations, it is fortuitous that this study is sufficiently pow-
ered for the major end points without inclusion of the 115
patients receiving thrombolytic therapy.
Rationale for this trial. Clearly, prospective, long-term
trials utilizing risk stratification and comparative diagnostic
approaches are needed to determine the optimal management
strategy for survivors of non–Q wave AMI and to ascertain the
cost-effectiveness of an invasive versus conservative manage-
ment in terms of clinical outcomes, resource utilization and
other health care outcomes.
The conduct of such a multicenter trial like VANQWISH
within the Department of Veterans Affairs affords certain
advantages and disadvantages. Because the veteran population
is typically older and often sicker than other patient groups, the
associated comorbidity might be expected to result in a higher
risk for adverse outcomes. Moreover, the Department of
Veterans Affairs health care system is less influenced by
physician referral pressures and reimbursement practices in
choosing postinfarction diagnostic or therapeutic procedures,
thus minimizing the potential for a priori selection bias.
However, the low percentage of women veterans limits gener-
alizability of overall trial findings to female patients after
NQMI.
Conclusions. The VANQWISH trial represents the larg-
est, most comprehensive clinical comparison of long-term
management strategies in patients recovering from NQMI.
Data from this trial will hopefully clarify the optimal diagnostic
and therapeutic approach to managing patients with this
prevalent clinical disorder.
Appendix
Participating Investigators and Institutions for
Cooperative Study 368 (VANQWISH Trial)
Study Chairman’s Office (Boston). William E. Boden, Study Chairman;
Hugh Dai, Diane M. Joyce, Project Coordinators; Patricia A. Crawford, Program
Assistant.
Department of Veterans Affairs Medical Centers. Albuquerque, New Mexico:
Michael Crawford, Matthew R. Holland, Karen Wagoner; Cincinnati, Ohio:
Laura Wexler, Virginia Thomas; Fresno, California: Prakash C. Deedwania,
Enrique Carbajal, Rebecca Kanefield; Gainesville, Florida: Carl J. Pepine, J.
Russell Green, Jr., Marian Limacher, Eileen Handberg-Thurmond, Nancy Davis;
Chicago, Illinois: Ming H. Hwang, Sandra Lemoine; Houston, Texas: Alvin S.
Blaustein, Cynthia Rowe; Lexington, Kentucky: Craig A. Chasen, Penelope
Frazier; Little Rock, Arkansas: Marvin L. Murphy, James E. Doherty, Eugene S.
Smith III, Joe B. Calkins, Jr., Anita Bierle; Loma Linda, California: David D.
Ferry, Alan Jacobson, Geir Frivold, Karen Okubo; Nashville, Tennessee: Raphael
F. Smith, Stewart Levine, Randalyn Bruce; Palo Alto, California: John Giaco-
mini, Carole Stepp; Richmond, Virginia: Robert Jesse, Anthony Minisi, Cather-
ine Murphy; San Antonio, Texas: Robert A. O’Rourke, Avanindra Jain, Carolyn
Patterson; San Diego, California: Alan Maisel; Seattle, Washington: Kenneth
Lehmann, James Caldwell, Scott Ferris; Saint Louis, Missouri: Henry Stratmann,
Liwa Younis, Linda Conwill; Tampa, Florida: Robert G. Zoble, Guillermo B.
Cintron, J. Thompson Sullebarger, Julie Umberger.
Cooperative Studies Program Coordinating Center (Palo Alto, California).
Philip W. Lavori, Chief; Dan Bloch, Bruce Chow, Marika K. Iwane, Ronald G.
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Thomas, Biostatisticians; Andres Busette, Lenore Sheridan, Raymond Yezzi,
Statistical Assistants; Sheila Jones, Juawanna King, Research Assistants; Kathleen
Small, Administrative Officer.
Cooperative Studies Program Clinical Research Pharmacy Coordinating
Center (Albuquerque, New Mexico). Clair M. Haakenson, Michael J. Miller,
Clinical Research Pharmacists; Loretta A. Guidarelli, Study Coordinator ; Linda L.
Vasquez, Computer Assistant; Frances Chacon, Cindy Tripp, Gloria Garcia,
Production Controllers; Julie Price, Research Assistant.
End Points Committee. Christopher P. Cannon, Chairman, Brigham and
Women’s Hospital, Boston, Massachusetts; Kim A. Eagle, University of Michigan
Medical Center, Ann Arbor, Michigan; Douglas W. Losordo, St. Elizabeth’s
Hospital, Boston, Massachusetts.
Data Monitoring Board. Bertram Pitt, Chairman, University of Michigan
Medical Center, Ann Arbor, Michigan; Mark A. Moskowitz, University Hospital,
Boston, Massachusetts; Arthur J. Moss, University of Rochester Medical Center,
Rochester, New York; Robert F. DeBusk, Stanford University School of Medicine/
Medical Center, Palo Alto, California; Stanley P. Azen, University of Southern
California, Los Angeles, California; Robert C. Schlant, Emory University School of
Medicine, Atlanta, Georgia; Janet Wittes, Statistics Collaborative, Inc., Washing-
ton, D.C.
Core Laboratories. Robert E. Kleiger, Electrocardiography Core Laboratory,
Jewish Hospital/Washington University School of Medicine, St. Louis, Missouri;
Jeffrey A. Leppo, Nuclear Cardiology Quality Assessment Laboratory, University of
Massachusetts Medical Center, Worcester, Massachusetts; Richard A. Kerensky,
Carl J. Pepine, Coronary Angiography Quality Assessment Laboratory, University of
Florida, Gainesville, Florida.
Quality Assurance. The Study Chairman’s Office reviewed and approved all
coronary angiography requests for patients who were randomized initially to the
conservative strategy. The Study Chairman had no knowledge of the trial end
points and clinical events during patient enrollment. The Coordinating Center
centrally randomized patients and conducted internal data checks and external
data checks with national data bases and conducted site visits. The Nuclear
Cardiology Core Laboratory certified sites in the interpretation of nuclear studies
by utilizing phantom studies of unknown radionuclide ventriculograms and
planar thallium perfusion scintigrams. This laboratory reviewed a 20% random
sample of all thallium studies. The Coronary Angiography Core Laboratory
overread baseline coronary angiograms using standard Coronary Artery Surgery
Study (CASS) coronary angiography guidelines. The Electrocardiography Core
Laboratory overread all study ECGs and provided the End Points Committee
with blinded review of relevant ECGs for suspected study end points. The End
Points Committee adjudicated all suspected study end points, including cardiac
etiology of deaths, nonfatal reinfarctions, ischemic cardiac events resulting in
rehospitalization and procedure-related cardiac events. The Data Monitoring
Board was an independent committee that reviewed semiannual interim reports
of study data for safety and efficacy and the possible need for early trial
termination. This board met annually in a joint meeting with the Human Rights
Committee, which consisted of lay and clinical persons who ensured the safety
and ethical treatment of patients through a review of study data, site visits and
patient interviews.
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